Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 May;10(2):261-264.
doi: 10.1007/s13730-020-00560-z. Epub 2021 Jan 2.

Fecal microbiota transplantation for membranous nephropathy

Guanzhou Zhou  1   2 , Jiaqi Zeng  1   2 , Lihua Peng  1 , Lei Wang  1 , Wei Zheng  3 , Di Wu  4 , Yunsheng Yang  5
Affiliations
Case Reports

Fecal microbiota transplantation for membranous nephropathy

Guanzhou Zhou et al. CEN Case Rep. 2021 May.

Abstract

Membranous nephropathy is a pathological type of nephrotic syndrome. Current treatments including supportive therapy, corticosteroids, immunosuppressive agents are not effective for all patients. New therapies are needed to treat the disease safely and effectively. Gut microbiota may contribute to the pathogenesis of this disease. Fecal microbiota transplantation (FMT) has made achievements in many diseases. Here, we report a case in which FMT is used to treat a patient with membranous nephropathy and chronic diarrhea, whose symptoms ameliorated and renal function improved.

Keywords: Fecal microbiota transplantation; Gut microbiota; Membranous nephropathy.

PubMed Disclaimer

Conflict of interest statement

All the authors have declared no conflict of interest.

Figures

Fig. 1
Fig. 1
Some related laboratory test results’ changes before and after twice FMT treatments. a Serum albumin; b total serum protein; c serum creatine; d serum urea; e 24 h urine proteins; f serum PLA2R. Day 0: before the first FMT; Day 7: after the first FMT; Day 30: before the second FMT; Day 37: after the second FMT
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. van de Logt AE, Fresquet M, Wetzels JF, Brenchley P. The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery. Kidney Int. 2019;96(6):1292–1302. doi: 10.1016/j.kint.2019.07.014. - DOI - PubMed
    1. Couser WG. Primary membranous nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983–997. doi: 10.2215/CJN.11761116. - DOI - PMC - PubMed
    1. Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23(8):1416–1425. doi: 10.1681/ASN.2012020181. - DOI - PMC - PubMed
    1. Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381(1):36–46. doi: 10.1056/NEJMoa1814427. - DOI - PubMed
    1. Ondrussek-Sekac M, Navas-Carrillo D, Orenes-Pinero E. Intestinal microbiota alterations in chronic kidney disease and the influence of dietary components. Crit Rev Food Sci Nutr. 2020 doi: 10.1080/10408398.2020.1761771. - DOI - PubMed

Publication types

LinkOut - more resources